A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2015
At a glance
- Drugs Eflornithine (Primary) ; Sulindac (Primary)
- Indications Colorectal cancer; Intestinal polyps
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.